The Lancet Oncology on X: NEW: phase 2 GORTEC 2014-01 TPExtreme trial: TPEx (cetuximab+docetaxel+cisplatin) vs EXTREME (platinum+fluorouracil+cetuximab) in recurrent or metastatic head and neck squamous-cell carcinoma #headandneckcancer
![The Lancet Oncology on X: NEW: phase 2 GORTEC 2014-01 TPExtreme trial: TPEx (cetuximab+docetaxel+cisplatin) vs EXTREME (platinum+fluorouracil+cetuximab) in recurrent or metastatic head and neck squamous-cell carcinoma #headandneckcancer](https://pbs.twimg.com/media/Ev8wYsGXcAICBnu.jpg)
![](https://ars.els-cdn.com/content/image/1-s2.0-S0959804919304782-gr2.jpg)
Cetuximab, fluorouracil and cisplatin with or without docetaxel
![](https://www.nejm.org/na101/home/literatum/publisher/mms/journals/content/nejm/2008/nejm_2008.359.issue-11/nejmoa0802656/production/images/img_medium/nejmoa0802656_f1.jpeg)
Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
Frontiers A Multicenter Phase II Trial of Docetaxel, Cisplatin
![](https://media.springernature.com/m685/springer-static/image/art%3A10.1007%2Fs12672-022-00603-0/MediaObjects/12672_2022_603_Fig1_HTML.png)
Changes in neutrophile-to-lymphocyte ratio as predictive and
![](https://pbs.twimg.com/media/D8Sj7YXXsAAwO2e.jpg)
GEDEFO on X: Docetaxel can be substituted for 5-FU in combination
![](https://www.thelancet.com/cms/attachment/5b1d3b86-6c8c-4af3-ab9f-dcfa44b4344f/gr3_lrg.jpg)
Radiotherapy plus cetuximab or cisplatin in human papillomavirus
![](https://media.springernature.com/m685/springer-static/image/art%3A10.1007%2Fs40261-020-00973-9/MediaObjects/40261_2020_973_Fig3_HTML.png)
Pembrolizumab vs the EXTREME Regimen in Recurrent or Metastatic
![](https://www.frontiersin.org/files/Articles/464084/fonc-09-00668-HTML/image_m/fonc-09-00668-t001.jpg)
Frontiers The Evolving Role of Taxanes in Combination With
![](https://www.thelancet.com/cms/attachment/e935229a-2227-4da4-a9e3-580195475300/gr3.gif)
Neoadjuvant cisplatin and fluorouracil versus epirubicin
![](https://www.frontiersin.org/files/MyHome%20Article%20Library/1226939/1226939_Thumb_400.jpg)
Frontiers TTCC-2019-02: real-world evidence of first-line
Cetuximab, docetaxel, and cisplatin as first-line treatment in
![](https://ascopubs.org/na101/home/literatum/publisher/asco/journals/content/jco/2014/jco.2014.56.32.issue-27/jco.2014.56.32.issue-27/20160922/jco.2014.56.32.issue-27.largecover.png)
Randomized Phase III Trial of Concurrent Accelerated Radiation